LAUSR

BACKGROUND AND OBJECTIVE Different surgical approaches have been described for selective amygdalohippocampectomy (SeAH) in patients with pharmacoresistant temporal lobe epilepsy (TLE). We report the results of the innovative trans-superior temporal gyrus (trans-STG) approach in a monocentric patients' series. METHODS We reviewed the patients' characteristics, post-operative outcomes, and complications in a series of 8 consecutive TLE patients operated on using the trans-STG approach and recruited between November 2015 and April 2017. RESULTS Over a mean 2,5-year follow-up period, 7/8 patients (87,5%) remained seizure-free (Engel 1). Only one (12,5%) was not cured (Engel 3) without clear explanation for treatment failure. Mean operative time was 237 minutes, representing a shortage of 80 minutes when compared to our historic trans-sylvian approach. No peri-operative death was recorded nor visual field defect/visual acuity impairment due to the approach. One patient suffered from a left posterior thalamo-capsular stroke. CONCLUSION Trans-STG approach is feasible, fast, and safefor SeAH in drug refractory TLE patients. This approach allows preservation of the optic radiation but cuts part of the uncinate fasciculus and potentially the anterior aspect of the anterior bundle of the midlle longitudinal fasciculus.